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Abstract: In HIV-1 management, eradication of the virus from sanctuaries represents a major and challenging goal. The genital tract, 
gut associated lymphoid tissue, lymph nodes, central nervous system, macrophages and latently infected CD4+ T lymphocytes are 
typical sites where HIV-1 compartmentalizes. To circumvent this problem, a consistent number of studies have focused on improving 
ARVs (antiretroviral drugs) delivery into sanctuary sites and different nanotechnological approaches have been developed. Cellular 
HIV-1 sanctuaries (i.e. macrophages) can be reached by nanoformulation of ARVs or by activation of latently infected cells. 
Anatomical sanctuaries (i.e. brain or male genital tract) can be addressed by increasing the permeation of ARVs across tissue barriers, 
such as the blood-brain barrier or the blood-testis barrier, while ARVs concentration in lymph nodes can be enhanced by drug 
encapsulation in CD4-targeted nanoparticles. 
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1. Introduction 
In the era of tailored cure and global progression of 
medicine in most fields, eradication of HIV-1 
infection is still a clinical challenge. ARV (although 
current antiretroviral) therapies reduce plasma HIV-1 
below detectable levels in a consistent proportion of 
subjects [1], to date, a complete viral eradication is 
unfeasible. Even a five drugs-regimen in early (< 6 
months) HIV-1 infection, which represents the 
strongest therapy in the best HIV-1 setting, does not 
improve the reservoir reduction in terms of proviral 
DNA, cell-associated RNA, replication-competent 
virus (all from purified blood CD4+ T cells), or gut 
proviral DNA [2]. The major cause of failure to 
eradicate is the persistence of the virus in certain 
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physiological reservoirs. These HS (HIV-1 sanctuaries) 
can be defined as anatomical (i.e. central nervous 
system, genital tract, gut-associated lymphoid tissue, 
lymph nodes) or cellular (i.e. latently infected CD4+ T 
cells, macrophages) protected sites, which are almost 
impermeable to ARVs action and in which HIV-1 is 
able to replicate despite treatments, thus preventing 
any possibility of cure [3]. Nowadays, a combination 
of ARVs that target multiple steps of HIV-1 
replication (highly active antiretroviral therapy, 
HAART), represents the standard of care for HIV-1 
infection. However all these drugs belong to different 
classes with different pharmacokinetic profiles. 
In this scenario, nanotechnology for HIV-1 therapy 
is an exciting field of research, since: (1) 
nanoformulation may significantly improve the 
bioavailability and pharmacokinetic profile of ARVs 
allowing them to penetrate into HS for a proper 
eradication of the virus; (2) nanoparticles are efficient 
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drug delivery systems, which could combine several 
ARVs, thus providing a real hope for HIV-1 cure. 
Nanotechnological strategies for HIV-1 therapy have 
been investigated for more than 20 years. The first 
evidence that nanotechnology can improve ARV 
delivery comes from an experimental study in 1992, a 
few years after HIV-1 discovery. 
Polyalkylcyanoacrylate nanoparticles were found to 
be promptly phagocytized by HIV-1-infected 
macrophagesin vitro, promoting the incorporation of 
delivered azidothymidine into the target cells [4]. 
Since that study, a significant part of the 
nano-research has focused on improving the 
bioavailability of ART (antiretroviral therapy). Since 
2009, Gendelman and colleagues have developed the 
so-called “nanoART”, a polymer excipient-coated 
drug nanosuspension with high drug loading capacity, 
controllable size and charge, and tunable surface 
conjugation [5, 6]. NanoART demonstrated a high 
efficacy in controlling HIV-1 infection, with more 
than 1000-fold reduction in viral load upon weekly 
injections in murine models [7]. This nanoparticle can 
be efficiently internalized into monocyte-derived 
macrophages, acting as delivery systems of ARVs to 
these HIV-1 reservoirs, and the ability of macrophages 
to take in and release nanoART is associated with an 
improved antiretroviral efficacy in infected cells [8, 9]. 
Although the role of nanotechnology in improving 
ARV's bioavailability to infected cells has been 
widely described, overcoming HIV-1 sanctuaries 
remains a great challenge. Indeed, the contribution of 
nanoformulation in “shuttling” ARVs into HS is still 
poorly investigated. With regard to the CNS (central 
nervous system), nanoparticles that are able to 
improve drug permeation across the BBB (blood brain 
barrier) could allow ARVs to reach brain 
HIV-1-sensitive CD4+ cells. This goal could provide 
an exciting new perspective on HIV-1 therapy, since 
98% of ARVs are not able to reach this HIV-1 
reservoir [10]. Overcoming the BTB (blood-testis 
barrier) would similarly aid in the penetration of 
ARVs into the MGT (male genital tract). In the lymph 
nodes, where the optimal ARV concentration is 
unknown and challenges presented by the presence of 
different types of cellular reservoirs should be faced 
by conjugating ARVs to anti-CD4-targeted 
nanoparticles. 
Purpose of this review is to describe HIV-1 
sanctuaries and the principal biological barriers 
hindering delivery of ARVs, and to provide an 
overview of the nanotechnological approaches 
implemented to properly address ARV delivery to 
HIV-1 reservoirs. The accomplishment of these 
studies will likely have a strong clinical impact on 
HIV-1 management, increasing the efficacy of ARVs 
and limiting their side effects.  
2. HIV-1 Sanctuaries 
2.1 Anatomical Sites: Central Nervous System, Male 
Genital Tract and Lymph Nodes 
CNS is considered one of the most important 
anatomical sanctuaries for HIV-1. It displays an 
elevated concentration of infected macrophages and 
microglial cells, which promote inflammatory 
escalation and lead to astrogliosis and 
neurodegeneration [3, 11]. The low permeability of 
BBB is responsible for the exclusion of vast majority 
of antiretroviral drugs from CNS. The BBB is 
composed of a layer of brain microvascular 
endothelial cells, reinforced by pericytes and 
astrocytes endfeet, which strictly prevent the access to 
all the hydrosoluble drugs with a molecular weight 
higher than 400 Da. Molecules unable to cross the 
BBB because of their size, weight or polarity, can 
cross the BBB only if transported by 
receptor-mediated transcytosis. Indeed, the 
cerebrospinal fluid has been demonstrated to be 
inaccessible to most ARVs, such as nelfinavir, 
ritonavir [12], and saquinavir [13], as well as the 
nucleotide analogue tenofovir [14] and the fusion 
inhibitor enfuvirtide [15]. This fact is clinically 
relevant, since HIV-1-related brain infection leads to a 
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broad spectrum of complex neurocognitive and 
organic disorders, altogether called “neuroAIDS” [10]. 
It includes cognitive decline with impairment of 
attention, learning and mood disorders up to dementia, 
and other manifestations such as multifocal 
leukoencephalopathy, primary CNS lymphoma and 
tuberculous or cryptococcal meningitis [16]. The 
advent of ART has drastically reduced the most severe 
forms of neuroAIDS, but the prevalence of milder 
neurologic signs (e.g., asymptomatic neurocognitive 
impairment and mild neurocognitive impairment) 
remains high, affecting up to half of all 
HIV-1-infected individuals [17] and conferring a 2- to 
6-fold increased risk for the development of 
symptomatic HIV-1-associated neurocognitive 
disorder [18]. In the ART-naive population, 
neurocognitive impairment has been associated with 
higher HIV-1 RNA and DNA levels in plasma and 
cerebrospinal fluid, and with several markers of 
inflammation and monocyte activation [19, 20]. A 
huge amount of HIV-1 DNA in the peripheral blood 
has been associated with severe neurocognitive 
impairment, independently of HIV-1 RNA plasma 
load [21]. In the setting of virologic suppression 
following ART, greater HIV-1 DNA levels contribute 
to persistent immune activation in tissues, including 
the brain [22], which in turn contributes to 
neurodegeneration and cognitive impairment [23]. 
Finally, there is evidence that the cerebrospinal pool 
of HIV-1 is one of the major obstacles to eradication 
[24] and therefore strategies to make ARVs overcome 
the BBB are urgently needed. 
Another anatomical barrier to the ARVs is 
represented by the blood-testis barrier, one of the 
tightest blood-tissue barriers in mammalians. It 
separates an apical compartment, where meiosis, 
spermiogenesis and spermiation occur, from a basal 
compartment, where the spermatogonial 
differentiation and the development up to the 
preleptotene spermatocyte stage take place. BTB is a 
dynamic barrier: a new BTB is produced behind the 
transiting spermatocytes, while the previous layer 
undergoes degeneration above the cells in transit [25]. 
The tightness of the BTB is due to specialized tight 
junctions between the Sertoli cells, which hamper the 
intercellular diffusion of hydrophilic molecules. The 
penetration of ARVs into the MGT, expressed as the 
ratio of drug concentration in semen to plasma 
samples, was analysed by Else and collegues on a 
wide variety of ARVs belonging to different classes 
[26]. The rank order of accumulation is reported in 
Table 1. The BTB has a high clinical significance 
since HIV-1 is sexually transmitted. In most cases, 
although viral load is completely depleted from blood, 
HIV-1 remains in semen [27]. Reasons of such HIV-1 
persistence are still to be investigated in detail, but it 
seems that both the BTB and the presence of 
HIV-1-infected macrophages in urethra and other 
male genital organs could be responsible for active 
release of HIV-1 in semen of patients undergoing 
HAART, thereby increasing the probability of HIV-1 
transmission in sexually active patients [28, 29].  
Despite the effectiveness of ART, HIV-1 remains 
detectable in lymph nodes [30], and an insufficient 
 
Table 1  Rank order of ARV accumulation into the MGT 
(male genital tract).  
Rank order ARV class 
1 
Lamivudine 
Zidovudine 
Tenofir 
Didanosine 
NRTIs 
NRTIs 
NRTIs 
NRTIs 
2 
 
Stavudine 
abacavir 
INSTIs 
PIs 
3 raltegravir  EIs 
4 indinavir maraviroc nevirapine  
PIs 
EIs 
NNRTIs 
5 
efavirenz 
amprenavir 
atazanavir 
darunavir  
NNRTIs 
PIs 
PIs 
PIs 
6 lopinavir ritonavir 
PIs 
PIs 
7 saquinavir  PIs 
8 enfuvirtide FIs 
NRTIs: nucleoside/nucleotide reverse transcriptase inhibitors; 
NNRTIs: non-nucleoside reverse transcriptase inhibitors; 
INSTIs: integrase strand transfer inhibitors; PIs: protease 
inhibitors; EIs: entry inhibitors; FIs: fusion inhibitors. 
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exposure of lymphoid tissue to ARVs is a crucial 
aspect with regards to complete viral eradication. 
Indeed, Kinman et al. demonstrated that indinavir 
concentration in lymph node mononuclear cells was 
about one third of that found in similar cells within the 
blood in HIV-1-positive patients [29]. Moreover, a 
recent study on 12 HIV-1-infected patients treated 
over six months with five of the most frequently used 
ARVs [tenofovir disoproxil fumarate/emtricitabine, in 
combination with efavirenz (n = 6), 
atazanavir/ritonavir (n = 4), and darunavir/ritonavir (n 
= 2)], demonstrated that concentration of the drugs in 
lymph nodes was much lower than that detected in the 
peripheral blood [31].  
2.2 Cellular Sites 
Lymphatic tissues can be considered HS not only 
for the poor accessibility to ARVs, but also for the 
abundant presence of major cellular reservoirs in these 
sites. A study on SIV-infected macaques, treated with 
a combined antiretroviral therapy for 1 year, showed 
that viral RNA was undetectable in plasma, while 
remained detectable in productively infected T 
lymphocytes. These cells were predominantly found 
clustered in the follicles of mesenteric lymph nodes, 
and were responsible for the rebound of plasma 
viremia upon cessation of therapy [32]. 
However, the main cellular reservoirs for latent 
HIV-1 infection are the central memory (TCM) and the 
transitional memory (TTM) CD4+ T cells. In patients 
subjected to early HAART treatment, TCM cells 
represent a limited size reservoir, which decreases at a 
very slow rate as a consequence of activation of 
antigen-induced responses, eliminating a fraction of 
infected cells. TTM cells represent the main reservoir 
in individuals where HAART treatment is started at a 
later stage. Here, a persistent proliferation of CD4+ 
TTM cells, although at low levels, is maintained by 
high amounts of interleukin 7 [33]. 
Another cellular sanctuary has been recently 
recognized in the CD4+ TSCM (T memory stem cells). 
This long-term HIV-1 reservoir seems to be related to 
TSCM intrinsic properties, such as self-renewal, escape 
from apoptotic mechanisms and long time survival 
[34]. Cellular sanctuaries are also represented by 
monocytes, macrophages, naive CD4+ T cells, 
astrocytes, and follicular cells [3]. In particular, 
macrophages act as chronic and latent viral reservoirs 
in infected patients [35, 36], because the life span of 
HIV-1 infected cells is prolonged by sophisticated 
mechanisms adopted by the virus within these cells. 
Outstanding examples are the production of 
pro-survival factors, induced by the viral envelope 
glycoprotein, which downregulate the death receptor 
(tumor necrosis factor-related apoptosis-inducing 
ligand [TRAIL]-R1) [37], or the induction of the 
telomerase activity, which is known to contribute to 
cellular protection against oxidative stress [38]. 
3. The P-glycoprotein: A Molecular Barrier 
to ARVs 
In addition to the anatomical barriers described 
above, such as BBB and BTB, the P-gp 
(P-glycoprotein) system represents a crucial molecular 
barrier to various ARVs. The P-glycoprotein is a drug 
efflux transporter which pumps drugs out of the cell, 
preventing their intracellular accumulation [39], and it 
has a central role in cellular detoxification not only 
during cytotoxic chemotherapy or antibiotics 
treatment, but also treatment with ARVs. Indeed, P-gp 
is a major cause for the reduced concentration of 
ARVs within cerebrospinal fluid and semen, since it is 
overexpressed in both BBB and BTB [39]. P-gp is also 
largely expressed in intestinal mucosa, thus 
representing a real obstacle in oral absorption of some 
ARVs such as saquinavir [40]. It has been recently 
demonstrated that HIV-1 exposure actively increases 
P-gp expression in bowel mucosa, decreasing the 
concentration of orally administered ARVs within the 
gut-associated lymphoid tissue [41]. In this context, it 
has been demonstrated that P-gp is overexpressed in 
the cervico-vaginal mucosa as well, which is the target 
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of some recent studies on HIV-1 sexual transmission 
[42, 43]. Indeed, various pharmacological 
formulations of ARVs have been tested vaginally or 
orally for a pre-exposure prophylaxis of HIV-1 in 
women, but the presence of P-gp significantly 
diminishes the efficacy of the administered ARV [43]. 
Finally, P-gp can be highly overexpressed in response 
to therapy administration, as well documented by 
studies on CD8+ T lymphocytes isolated from the 
peripheral blood of HIV-1-infected patients under 
ARV treatment [44]. In conclusion, P-gp system plays 
a crucial role in preventing the penetration of ARVs 
into HS, and overcoming this barrier is of primary 
importance for proper viral eradication. 
4. Nano-delivery Systems to Catch the 
Anatomical HIV-1 Sanctuaries 
4.1 Central Nervous System 
Overcoming of anatomical barriers, aimed to reach 
effective concentration of ARVs in specific HIV-1 
reservoirs, has been widely investigated in the last 
decade by various nanotechnological approaches 
(Table 2). In this context, the most studied sanctuary 
is definitely the CNS, since ability of nanoformulation 
to allow or increase permeation of ARVs across the 
BBB is a strongly appealing clinical feature. In 2008, 
Xu and colleagues designed a Tf 
(transferrin)-conjugated quantum rod for the specific 
targeting of BBB. This Tf-conjugated nanoparticle 
was able to cross an in vitro BBB model by exploiting 
a receptor-mediated transport [45]. Indeed, it is known 
that BBB endothelial cells overexpress TfR 
(transferrin receptor) [46], which acts as a transporter 
for therapeutic biomolecules to the brain [47]. The 
same nanoparticle was then employed for the 
conjugation of saquinavir, and in vitro studies have 
demonstrated that the trans-BBB permeation of the 
nanoformulated ARV was higher than that of the free 
drug. As a consequence, a more efficient antiretroviral 
activity on HIV-1 infected peripheral blood 
mononuclear cells was demonstrated [48]. Another 
targeted  delivery of  ARVs across  the BBB has  been 
 
Table 2  Nanoparticles for the delivery of ARVs into HIV-1 sanctuaries.  
Sanctuary Nanoparticle Delivered ARV Experimental model 
Central nervous 
systems 
quantum rods-Tf [48] 
RMP-7/MMA–SPM-NP [49] 
TAT-NP [53] 
poly(ethylene oxide)–poly(propylene oxide) 
micelle [54] 
MYTS [55] 
magnetic liposome [56] 
folate-nanoART [57] 
saquinavir 
stavudine saquinavir 
delavirdine 
ritonavir 
efavirenz 
enfuvirtide 
AZTTP 
Atazanavir 
ritonavir indinavir efavirenz 
In vitro BBB model 
In vitro BBB model 
In vitro BBB and in vivo model
In vivo model 
In vitro BBB and in vivo model
In vitro BBB model 
In vitro BBB and in vivo model
Lymphoid tissue 
anti-HLA-DR immunoliposome [59] 
lipid NP [60] 
PEG-lipid NP [61] 
Man-liposome [62] 
PEG-elastic liposome [63] 
folate-nanoART [64] 
indinavir  
indinavir 
indinavir 
zidovudine 
zidovudine  
ritonavir atazanavir 
In vivo model 
In vivo model 
In vivo model 
In vivo model 
In vivo model 
In vivo model 
Male genital tract PLGA [65] 
lopinavir 
ritonavir 
efavirenz 
In vivo model 
Cellular sanctuaries 
anti-CD4- lipid NP [70]  
anti-CD4-immunoliposome [71] 
lipid NP- bryostatin-2 [72] 
glycine/mannose-PPI [73] 
tuftsin-PPI [74]  
mannose-PPI [75]  
indinavir  
saquinavir nevirapine 
nelfinavir 
efavirenz 
efavirenz 
lamivudine 
CD4+- cells 
CD4+ Jurkat T cells 
CD4+ T-cells and in vivo model
monocytes/macrophages 
macrophages 
macrophages 
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obtained with MMA-SPM 
(methylmethacrylate-sulfopropylmethacrylate) 
nanoparticles functionalized with the bradykinin 
analog RMP-7, a receptor agonist of the bradykinin 
type II receptor which is primarily expressed in 
neuronal and vascular tissues. 
These NPs loaded with stavudine, saquinavir or 
delavirdine have demonstrated enhanced permeation 
across the BBB, exploiting both the transcellular 
transport of NPs as well as RMP-7-mediated increase 
of paracellular permeability [49]. 
Other nanoparticles have been designed as brain 
drug delivery systems by exploiting the penetration 
capability of molecules conjugated on their surface, 
such as cell penetrating peptides and analogues [50], 
or the peculiar chemical-physical properties of NP 
shell (i.e. pluronic block and PMA-based amphiphilic 
copolymers) [51, 52]. In 2008, Rao et al. demonstrated 
that trans-activator of TAT (transcription) 
peptide-conjugated nanoparticles were able to increase 
the CNS transport of the encapsulated ritonavir across 
the BBB in mouse [53]. Encapsulation of efavirenz 
into a poly (ethylene oxide)—poly(propylene oxide) 
micelle increased its bioavailability into the CNS upon 
intranasal administration [54]. In 2015, our group 
demonstrated that enfuvirtide conjugated to 
PMA-coated iron oxide NPs is allowed to cross BBB 
in vitro and in vivo. In this case, the nano-drug 
penetration into BBB endothelial cells was mediated 
by the absorption of the amphiphilic coating on cell 
membrane, and upon nanocomplex dissociation within 
the endosomal/lysosomal complex, enfuvirtide was 
released in brain parenchyma.[55] Since enfuvirtide   
is a structurally complex molecule known to be  
unable to reach the cerebrospinal fluid in a detectable 
amount [15], hypothetically, this study may suggest a 
suitable system for the passage of most ARVs across 
the BBB. 
Although liposomes are the most utilized drug 
carriers, their application as ARV delivery systems to 
the CNS is limited by inefficient loading of 
water-soluble drugs, low stability, and leakiness of 
loaded drug during storage [10]. Among several 
studies performed with liposomes [6], interesting 
results have been obtained with magnetic liposomal 
nanoformulations of azidothymidine 5’-triphosphate, 
which is the active form of azidothymidine. These 
magnetic liposomes can transmigrate across BBB in 
vitro, either directly or by a monocyte-mediated 
transport, under the influence of an external magnetic 
field [56]. 
As already mentioned, nanoARTs have also proved 
as valid tools for CNS penetration upon encapsulation 
in macrophages. Atazanavir, ritonavir, indinavir, and 
efavirenz, formulated as nanoART, and internalized 
into brain mononuclear phagocytes were efficiently 
translocated to human BBB endothelial cells by a 
cell-to-cell contact mechanism. Permeation into the 
CNS, especially that for folate-coated nanoART, was 
associated with decreased viral load and inflammation 
in the brain of HIV-1 infected mice [57]. 
4.2 Lymphoid Tissue 
Targeting of lymphoid tissue with nanoformulated 
ARVs has been investigated since 1999 when the first 
liposomes directed towards HLA-DR-expressing 
monocyte/macrophages and activated CD4+ T 
lymphocytes in this site were developed [58]. Three 
years later, it was demonstrated that the 
nanoformulation of indinavir in this NP was able to 
induce a 126-fold higher concentration of drug in the 
lymphoid tissue of injected mice, with a therapeutic 
window of at least 15 days post-injection [59]. In 2003, 
lipid NPs were used for the lymphatic delivery of 
indinavir in infected macaques, enhancing its 
peripheral and visceral lymph nodes concentration up 
to values 23-fold higher than in plasma and providing 
a significant virus load reduction both in lymphoid 
tissue and plasma [60]. This system was then 
optimized by saturation of indinavir lipid NPs with 
polyethylene glycol, obtaining a further enhancement 
of drug level in lymph nodes [61]. In 2008, 
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zidovudine-loaded liposomes with different surface 
charges were exploited to improve its delivery to 
lymphoid virus reservoir, demonstrating that 
negatively charged liposomes had higher 
accumulation in lymph nodes compared to positively 
charged nanoART [62]. Moreover, a surface coating 
with mannose, whose receptors are highly   
expressed on immune cells, induced a much higher 
lymphatic accumulation. In the same year, the 
transdermal administration of PEGylated liposomal 
zidovudine formulation induced a 27-fold higher 
accumulation of zidovudine in lymphoid tissues 
compared to free drug, likely associated to a higher 
uptake in lymphoid cells [63]. More recently, a 
specialized folate-modified nanoART, containing 
ritonavir and atazanavir, was loaded in macrophages, 
thanks to folate receptor-mediated cellular uptake, 
thus obtaining an efficient and long-lasting delivery of 
ARVs in mice lymph nodes after a single 
administration [64]. 
4.3 Male Genital Tract 
So far, no study about the permeation of 
nanoformulated ARVs across the BTB has been 
reported, with the only exception of a broad-spectrum 
research aimed to investigate the effect of 
nanocomplexation of ARVs on their distribution in 
different organs, including testes. The results of this 
study indicated that lopinavir, ritonavir and efavirenz 
administered into PLGA (Poly Lactic-co-Glycolic 
Acid) nanoparticles were able to accumulate in mice 
testes for up to 35 days [65], due to efficient 
entrapment, cellular uptake, retention and sustained 
release of drugs provided by these NPs [66]. 
Moreover, few other studies that investigated the 
biodistribution and systemic toxicity of iron, silver 
and gold nanocompounds administered to mice are 
available [67-69]. They describe a suitable distribution 
of these NPs in testes, thus suggesting a promising 
employment of inorganic nanoparticles for the 
delivery of ARVs into the male genital tract. 
5. Nano-delivery of ARVs to the Cellular 
Sanctuaries 
Most nanotechnological strategies for the delivery 
of ARVs to the cellular HIV-1 sanctuaries are based 
on the active targeting of the CD4 receptors (Table 2). 
CD4-targeted lipid NPs nanocomplexed with indinavir 
demonstrated a selective binding and uptake on 
CD4+-HIV-1 host cells, with an increased anti-HIV-1 
effect. The hypothesized delivery mechanism involved 
the interaction of the nanoformulation with membrane 
CD4, followed by their endocytosis, and 
pH-dependent endosomal escape of indinavir into the 
cell cytoplasm, where they inhibit the viral protease 
[70]. Very recently, a stealth anti-CD4-targeted 
immunoliposome loaded with saquinavir and 
nevirapine has been developed which demonstrated an 
efficient uptake of the drugs into CD4+ Jurkat T cells 
and an enhanced anti-viral efficacy at significantly 
lower concentrations when compared to the free drug 
[71]. Kovochich and colleagues designed lipid 
nanoparticles loaded with bryostatin-2, a protein 
kinase C activator able to activate latent HIV-1 
infections. These nanoformulations were 
demonstrated to target and activate CD4+ T-cells and 
stimulate latent virus production, both in vitro and in a 
humanized mouse model. The simultaneous 
incorporation of bryostatin-2 and the protease 
inhibitor nelfinavir gave rise to an optimized 
nanoformulated ARV that was able to both activate 
the latent virus expression and inhibit viral spread in 
HIV-1-infected T lymphoblastoid cells after 3 days of 
incubation [72]. 
Regarding macrophages reservoirs, nanoART has 
been demonstrated to efficiently translocate into these 
cells, thus exerting an increased anti-HIV-1 activity 
(see previous section) [8, 9]. Another model of 
Mo/Mac (monocytes/macrophages)-targeted 
nanoparticles was developed by Dutta and colleagues 
in 2007. They produced a 5th generation poly 
(propyleneimine) dendrimer (PPI)-based 
nanocontainer loaded with the antiretroviral efavirenz, 
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and conjugated with glycine and mannose to optimize 
its targeted delivery, improving the release kinetic of 
the drug in comparison to the non-targeted NP and 
overcoming limitations imposed by NP toxicity. The 
best ARV cellular uptake was obtained with the 
mannose conjugated dendrimer due to its interaction 
with lectin receptors [73]. Another strategy to 
specifically deliver efavirenz in 
monocytes/macrophages has been exploited 
functionalizing the NP surface with tuftsin, a peptide 
known to specifically bind macrophages and activate 
several cell functions, such as phagocytosis. This 
tuftsin-conjugated PPI improved drug release with 
negligible cytotoxicity, enhanced cellular uptake 
within macrophages and enhanced drug efficacy [74]. 
Mannose-conjugated PPI was also loaded with 
lamivudine [75]. Higher ARV macrophages uptake 
and antiretroviral activity were observed with the 
lectin-targeted nanoformulations, as compared to the 
non-targeted dendrimer or to the free drug.  
6. Nanotechnological Approaches for P-gp 
Barrier Overcoming 
With regards to the P-gp barrier, nanostructured 
lipid carriers have been recently developed to enhance 
saquinavir bioavailability upon oral administration. 
Interestingly, these nanoparticles were able to 
overcome P-gp-mediated efflux from bowel mucosa, 
allowing caveolae- and clathrin-mediated transcytosis 
of the drug, with subsequent absorption [76]. 
Currently, some chemical strategies combining 
antiretroviral activity with inhibition of P-gp are being 
tested in preclinical experiments and have yielded 
encouraging results, mainly regarding penetration of 
ARVs through the BBB [77, 78]. However, although 
potentially significant, ARVs nanoformulations to 
specifically overcome P-gp activity still remain poorly 
investigated. 
7. Conclusions 
Nanotechnology has been exploited to enhance the 
pharmacokinetic properties of ARVs, and some efforts 
have been attempted to make HIV-1 therapy penetrate 
through selective biological barriers to reach HIV-1 
replication sanctuaries. Preliminary results are more 
than encouraging. Certainly, further research is 
required to better define the antiretroviral activity 
once the nano-drug has passed through the barrier. 
Furthermore, the next step will be the multiple 
encapsulation of ARVs into a single nanoparticle for a 
smart contemporary targeting of HIV-1 replication 
and infection pathways. Combined together, 
nanoformulations containing multiple ARVs that are 
suited to cross physiological barriers could lead to the 
generation of a novel class of anti-HIV-1 drugs, with 
the possibility of a combined antiretroviral strategy for 
both anatomical and intracellular reservoirs of HIV-1. 
A prompt translation of preclinical results into clinical 
practice will hopefully revolutionize HIV-1 therapy in 
the next future. 
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